Through bioinformatics analysis and verification experiments in vivo and in vitro, Croset et al. identified many genes including osteoblastogenesis inhibition (e.g., DKK1), osteoclastogenesis stimulation (e.g., IL8, IL11), tumor cell invasiveness (e.g., connective tissue growth factor, ITGA5, ITGB3), and bone osteomimicry (e.g., RUNX2, CDH11) as inhibition targets of the miR-30 family, thus impeding breast cancer bone metastases 10. The gene discussed is RUNX2; the disease is neoplasm.